Target RWE at EASL 2025: Advancing HCC, MASH & PBC Research

Company shares latest MASH, HCC research, PBC Consensus Conference insights, and key liver disease findings at EASL Congress 2025.

DURHAM, N.C., May 9, 2025 /PRNewswire/ -- Target RWE, a leader in modern clinical evidence generation for complex diseases, today announced its presentations and strategic contributions at the EASL Congress 2025 in Amsterdam, Netherlands. Target RWE unveiled findings on MASH and HCC and contributed expert leadership to the highly anticipated PBC Consensus Conference on May 6th.

Enabling Smarter Decisions in a Changing Regulatory Landscape

With regulatory agencies increasingly requiring early, comprehensive evidence—especially in MASH and PBC—Target RWE's real-world insights are uniquely positioned to support biopharma companies in navigating complex go/no-go decisions, minimizing screen failure rates, and designing cost-effective studies. The company empowers stakeholders to:

• Identify MASH patients without invasive biopsies in clinical trials.
  
  
• Assess long-term outcomes and therapy patterns in PBC patients unresponsive to UDCA.
  
  
• Understand the impact of comorbidities on MASH treatment efficacy.
  
  
• Integrate patient perspectives on quality of life and treatment satisfaction.

By harnessing real-world data and advanced methodologies, Target RWE is transforming how researchers close evidence gaps, mitigate regulatory risk, and accelerate the development of liver disease therapies that truly improve patient outcomes. As liver disease care evolves, Target RWE remains a trusted partner in driving the future of data-informed clinical research.

Leadership at the PBC Consensus Conference

Further underscoring its leadership in hepatology, Target RWE's Co-Founder and Chief Medical Officer, Michael W. Fried, MD, FAASLD, will participate in the upcoming Consensus Conference on surrogate endpoints and real-world evidence in Primary Biliary Cholangitis (PBC). This pivotal pre-congress event, scheduled for May 6, 2025, at the RAI Amsterdam, aims to align on critical scientific, clinical, and regulatory priorities, including the development of reliable surrogate endpoints and the strategic use of real-world evidence in designing confirmatory clinical trials for PBC.

"Participating in this consensus conference offers a unique opportunity to collaborate with leading experts in refining endpoints and integrating real-world data into PBC research."  Said Michael W. Fried, MD, FAASLD, Co-Founder and Chief Medical Officer at Target RWE. "Aligning these priorities is essential for advancing therapeutic development and enhancing patient outcomes."

The Consensus Conference serves as a critical platform for harmonizing research methodologies and ensuring that clinical trials reflect real-world patient experiences, ultimately guiding the future of PBC therapy development.

Highlighting New Insights in HCC and MASH

Target RWE will present two novel abstract posters during EASL 2025, showcasing findings derived from its high-quality, longitudinal real-world data:

Type 2 diabetes increases the risk of progression to metabolic dysfunction-associated steatohepatitis-related cirrhosis in a real world setting.

This study, utilizing the TARGET-NASH cohort, found that individuals with MASH and type 2 diabetes have a significantly higher risk of progressing to compensated cirrhosis compared to those without diabetes, highlighting the need for early MASH screening in this population.

A comprehensive analysis of treatment patterns and outcomes for HCC patients undergoing transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) within the TARGET-HCC registry.

This analysis of the TARGET-HCC registry showed heterogeneous treatment patterns and outcomes in intermediate or advanced HCC patients treated with TACE or TARE, with a high rate of TACE/TARE unsuitability and low rates of subsequent systemic therapy use.

Target RWE offers crucial insights into the complexities of chronic liver diseases. Our MASH study underscores the significant impact of type 2 diabetes on disease progression, emphasizing the urgent need for proactive screening and management strategies to prevent the development of advanced liver disease in this high-risk population. The analysis of HCC treatment patterns sheds light on the challenges clinicians face in optimizing therapy sequences, revealing opportunities to improve adherence to treatment guidelines and ultimately enhance patient outcomes. Together, these presentations highlight the power of clinical evidence to inform clinical practice and drive advancements in liver disease care.

To learn more about Target RWE's real-world data solutions and how they are advancing liver disease research across MASH, HCC, and PBC, visit www.targetrwe.com or contact [email protected].

SOURCE Target RWE